Pazopanib Tablet: A Breakthrough in Targeted Cancer Therapy

Pazopanib is a multi-targeted tyrosine kinase inhibitor that falls under the class of oral anti-cancer agents. Each tablet typically contains 200 mg or 400 mg of pazopanib hydrochloride as the active ingredient. In addition to the active compound, the tablets contain excipients like magnesium stearate, microcrystalline cellulose, and hypromellose which facilitate tablet formation and stability.
Pharmacologically, Pazopanib demonstrates high specificity for several growth factor receptors, such as vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3, platelet-derived growth factor receptors (PDGFR)-α and -β, and c-kit. These receptors are known to play a critical role in angiogenesis and tumor proliferation. By targeting these receptors, Pazopanib effectively hampers the growth of new blood vessels that feed tumors, thereby starving the cancer cells.